Share Name Share Symbol Market Type Share ISIN Share Description
Plant Health Care LSE:PHC London Ordinary Share GB00B01JC540 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.50p +2.38% 21.50p 60,500 16:35:09
Bid Price Offer Price High Price Low Price Open Price
20.00p 23.00p 22.00p 22.00p 22.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 5.1 -9.2 -8.9 - 37.16

Plant Health Care (PHC) Latest News

More Plant Health Care News
Plant Health Care Takeover Rumours

Plant Health Care (PHC) Share Charts

1 Year Plant Health Care Chart

1 Year Plant Health Care Chart

1 Month Plant Health Care Chart

1 Month Plant Health Care Chart

Intraday Plant Health Care Chart

Intraday Plant Health Care Chart

Plant Health Care (PHC) Discussions and Chat

Plant Health Care Forums and Chat

Date Time Title Posts
11/3/201815:00 PHC - 24p - MASSIVE BOWL ON CHART TO 120p88
10/8/201610:25Throw away the artificial Fertilizer with Plant Health Care408
15/3/201117:27Plant Health Care20

Add a New Thread

Plant Health Care (PHC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-03-19 14:57:5820.508,0001,640.00O
2018-03-19 14:01:1522.0015,0003,300.00AT
2018-03-19 14:01:1522.0015,0003,300.00AT
2018-03-19 14:00:4822.0022,5004,950.00O
View all Plant Health Care trades in real-time

Plant Health Care (PHC) Top Chat Posts

Plant Health Care Daily Update: Plant Health Care is listed in the Chemicals sector of the London Stock Exchange with ticker PHC. The last closing price for Plant Health Care was 21p.
Plant Health Care has a 4 week average price of 19.60p and a 12 week average price of 14p.
The 1 year high share price is 35p while the 1 year low share price is currently 13.50p.
There are currently 172,822,881 shares in issue and the average daily traded volume is 32,639 shares. The market capitalisation of Plant Health Care is £37,156,919.42.
riddlerone: Sorry should have made that clearer Sarossa holding bought by Mr Griffiths
pugugly: riddlerone: > Remember the last placing where RG bought many of his shares was at 10P Not sure how much he will need to clear cost of previous acquisitions - RG acquisition notice Current positions of top 2 holders who will dictate action are Name Shares Held Percent of Issued Share Capital* Richard Griffiths 56,560,632 38.26% Lombard Odier Asset Management (Europe) Limited 35,378,401 29.93% Figures are as at As at 30 August 2017,
skyship: 24p!!! - Be very careful newcomers - note the massively dilutive placing going through at a mere 10p!
thomasthetank1: Read Liberum's note on Plant Health Care (PHC), out this morning, by visiting … “FY15 sales +9% (+15% in l.c.) with gross margins jumping to 62% from 51% last year with better product mix. A doubling R&D led to higher opex driving FY net loss to $8m vs. $6m in FY14. Net cash ended FY15 at $8.4m vs. $16.6m last year. Looking ahead we are not changing estimates materially. We expect further sales growth in existing products and R&D ramp up. PHC is excited by R&D progress and expects to introduce a 2nd peptide family for evaluation this year with trials for the 1st peptide family (Innatus 3G) going well. Innatus 3G license auctions are now expected in 2017/18. Licenses for its other peptide technologies are targeted earlier than this. We believe the recent share price fall is vastly overdone...”
19wizard: Any further news/views on the sharp decline in the share price since May.On the surface it will look buy at 50p.Sure there are some powerful reasons for the decline.
bobdouthwaite: "10:05 UK, 18th January 2011, by Plant Health Care revamp ties fortunes to Monsanto Plant Health Care's exit from direct sales has increased its vulnerability to setbacks at key customer Monsanto, whose slow seed revenues last spring prompted the alternative agrichemicals group to warn on its results. Plant Health Care revealed on Friday that it was pulling back from parts of its historic strategy, including direct sales, to focus on licensing deals it sees as a more lucrative revenue source. "If they want to get their products out to as many acres as possible, direct sales isn't really going to achieve that," a person familiar with the company's thinking told However, the company for now has a limited roster of licensees – albeit including big names such as Syngenta - for its products, which aim to enhance a plant's own capabilities to see off pests or take up nutrients. Plant Health Care's fortunes appear particularly tied to Monsanto, the world's biggest seeds group, which has a deal to apply the Harpin plant protection product as a seed treatment. 'Key to sentiment' "The key near-term share price driver is the rate at which revenues from Monsanto pick up over next quarter, which is the main selling period for soybean seeds," Evolution analyst Philip Sparks said. "Newsflow from Monsanto... will be key to sentiment." Indeed, Plant Health Care's shares could "meander" until data is forthcoming from Monsanto, whose slow sales last spring prompted the London-listed company to warn revenues would miss targets, sending the stock down by more than one-third. Investors have higher hopes for Monsanto this year, following a revamp of its pricing structure, and with strong crop prices improving farmers' willingness to splash out on genetically-enhanced seed. Monsanto shares have rebounded more than 50% from a nadir in late September. Mr Sparks kept a "buy" rating on Plant Health Care shares with a price target of 1650p. US disposal Plant Health Care's strategic revamp has involved the disposal of a US landscape and retail business which had been in part viewed as a way of enhancing direct sales. However, the business, sold for $4.65m, has been hit by the downturn in the US housing market, seeing operating profits drop to some $400,000 in the last financial year. "Investors attach little value to Plant Health Care's products businesses," Mr Sparks said. "The [group's] long term prospects are unaffected by the sale." Plant Health Care shares stood unchanged at 74.5p in morning deals" A price target of 1650p...I think not!
bobdouthwaite: Fwiw Monsanto's share price has fallen almost 40% since the beginning of the year, suggesting hard times for agribusiness more widely at the moment. I'm sure they did their due diligence with Harpin, but why would farmers pay for higher yielding Roundup Ready when soyabean futures look so poor?
mdrans1: PHC gets a half page buy recommendation in today's Shares Mag. "Plant Health Care to bloom again" Referring to the recent trading statement they say that Monsanto has "tightened it's stock controls, so in this case deferral of revenue should be just that and no more." They go on to list "several potential catalysts for a share price recovery." pruncorn They don't say anything to suggest they might be likely to run out of cash.
pruncorn: Trial results are fantastic. Why is the share price still going down? Is PHC likely to run out of cash?
stegrego: Shares mag comment: News food biotechnology giant Monsanto is accelerating the launch of its Roundup Ready 2 Yield (RR2) soybean seeds has positive implications for Plant Health Care (PHC:AIM) and its Harpin seed coating. House broker Evolution believes the Plant Health Care technology could produce royalties worth 350p per share compared to a 160p share price and investors should look to pick up stock. Monsanto raised its 2009/2010 volume target for its product from five million to six million acres up to seven million to eight million. Monsanto makes Roundup Ready seeds which can be used alongside its best selling weed-killer. The new seeds will incorporate Plant Health Care's Harpin seed coating which uses naturally-occurring proteins to boost root development and crop yields. The Harpin seed coating is the only one of Plant Health Care's products currently being commercialised. The company also has two further products under its belt which could be just as big. Plant Health Care's share price had a roller-coaster ride in December when the original announcement of the licensing deal with Monsanto sent the price up from 165p to 235p, only for it to be knocked back to its starting position two days later by Bayer's decision to terminate its contract for the other main product Myconate. Plant Health Care's shares have yet to recover from the German firm's decision although the £72 million cap is in ongoing discussions with other potential partners for Myconate and hopes to get someone on board within the next year. Harpin other's leg apart from the Monsanto deal is its use as a crop-spray additive, for which Plant Health Care is also seeking licensing partners. All three products are potential blockbusters and Plant Health Care only needs one to succeed to take it in to the big league.
Plant Health Care share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180320 00:29:24